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We assessed whether adding magnetic resonance (MR)-based features to a base model of 47 
clinically accessible risk factors (i.e., serological, radiographic, demographic, symptoms, and 48 
physical function) improved classification of adults who developed accelerated knee 49 
osteoarthritis (KOA) or not over the subsequent 4 years. We conducted a case-control study 50 
using radiographs from baseline and the first four annual visits of the Osteoarthritis Initiative to 51 
define groups. Eligible individuals had no radiographic KOA in either knee at baseline 52 
(Kellgren-Lawrence grade (KL) <2). We classified 2 groups matched on sex: 1) accelerated 53 
KOA: at least one knee developed advanced-stage KOA (KL=3 or 4) within 48 months and 2) 54 
did not develop accelerated KOA within 48 months. The MR-based features were assessments of 55 
bone, effusion/synovitis, tendons, ligaments, cartilage, and meniscus. All risk factors and MR-56 
based features were from the baseline visit. Classification and regression tree analyses were 57 
performed to determine classification rules and identify important variables. The base CART 58 
model and the base model + MR features each explained approximately 40% of the variability. 59 
Adding MR-based features to the base model yielded modest improvements in specificity (0.90 60 
versus 0.82) but lower sensitivity (0.62 versus and 0.70) than the base model. There was 61 
consistent evidence that serum glucose, effusion-synovitis volume, and cruciate ligament 62 
degeneration are important variables in classifying individuals who will develop accelerated 63 
KOA. We found common MR-based measures failed to dramatically improve classification. 64 
These findings also show a complex interplay among risk factors and a need to identify novel 65 






Knee osteoarthritis (KOA) is typically considered a slowly progressive disorder. 70 
However, at least 1 in 5 cases of incident KOA develop an accelerated form of KOA, 71 
progressing from no radiographic KOA to advanced-stage KOA within 4 years and often within 72 
12 months.1-3 Adults with accelerated KOA experience greater pain and functional disability than 73 
those with a typical onset of KOA.2; 4  Since the rate of disease onset offers only a short 74 
opportunity to intervene it would be helpful to classify people at-risk for accelerated KOA to 75 
create an opportunity to develop and deliver prevention strategies. We previously classified 76 
individuals using serum, radiographic, and demographic/anthropometric (age and body mass 77 
index) risk factors and explained 31% of the variability with high specificity but low sensitivity.5 78 
These results suggest that further analyses are needed with additional outcomes to better 79 
discriminate between individuals that will and will not develop accelerated KOA.  80 
Prodromal symptoms, functional disability, and magnetic resonance (MR) imaging-based 81 
knee assessments may help classify adults at risk for accelerated KOA. Adults who develop 82 
accelerated KOA often report greater prodromal symptoms and experience greater functional 83 
disability (e.g., slower walking speed) than those with typical KOA up to 3 years prior to 84 
radiographic onset.2 More recently, magnetic resonance (MR)-based measurements have also 85 
been identified as risk factors or early signs of accelerated KOA (e.g., effusion-synovitis, 86 
meniscal pathology).6-9  87 
The purpose of this study was to utilize classification and regression tree (CART) models 88 
to 1) assess the ability of MR features from the baseline visit to classify participants who will 89 
and will not develop accelerated KOA in the subsequent 4 years, and 2) determine whether 90 
adding baseline MR features to a base model that incorporated measures of symptoms, function, 91 
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radiographic, clinical, and demographic characteristics from the baseline visit improves 92 
classification of adults who will develop accelerated KOA over the subsequent 4 years. 93 
 94 
METHODS 95 
We conducted a case-control study using data and images from baseline and the first 4 96 
annual visits in the Osteoarthritis Initiative (OAI), a longitudinal multicenter observational 97 
cohort study of adults with or at risk of developing symptomatic KOA. Almost 4,800 participants 98 
(ages 45-79 years) were enrolled at 4 clinical sites in the United States between February 2004 99 
and May 2006.10 The protocol and detailed descriptions of the eligibility criteria are available at 100 
the OAI website.10 Institutional review boards at each of the 4 clinical sites and the OAI 101 
coordinating center approved the study. All participants provided informed consent.  102 
 103 
Case and Control Definitions 104 
Group assignment (accelerated KOA, typical KOA, and no KOA) was determined using 105 
annual radiographs from the baseline to the 48-month OAI visits. Eligible participants had 106 
Kellgren-Lawrence (KL) grade<2 at baseline in both knees. Cases were participants with 107 
accelerated KOA, defined as the development of advanced-stage KOA (KL grade 3 or 4) by the 108 
48-month visit. Typical KOA was defined as an increase in radiographic severity (KL grade) by 109 
month 48 (excluding those meeting the definition for accelerated KOA). No KOA was defined as 110 
no increase in the KL grade by month 48. Adults with typical KOA and no KOA were controls. 111 
We matched typical KOA and no KOA participants by sex to the accelerated KOA group 112 
(cases, n=54) in a 1:1:1 matching scheme. For the purposes of this study, typical KOA and no 113 
KOA participants were combined into one group to explore whether risk factors or combinations 114 
6 
 
of risk factors were able to classify adults who would develop accelerated KOA. The knee that 115 
first met the criteria for accelerated or typical KOA was included in the analysis. Participants 116 
with no KOA were side-matched to the accelerated KOA knee.  117 
To determine eligibility and group assignment we relied on bilateral weight-bearing, 118 
fixed-flexion posteroanterior knee radiographs. Central readers scored the KL grade of each knee 119 
(KL0 to KL4), with KL4 indicating the worst radiographic KOA severity. Good intra-rater 120 
reliability was observed for KL grade (weighted κ = 0.70 to 0.78).10 The protocol and data are 121 
publicly available at the OAI website (Files: kXR_SQ_BU##_SAS; versions 0.6, 1.6, 3.5, 5.5, 122 
6.3).10  123 
 124 
Candidate Measures from the Base CART Model 125 
Measures from the baseline visit that were clinically-accessible were chosen as candidate 126 
variables: radiographic assessments, demographic characteristics (age, sex, and body mass 127 
index), biospecimen measurements, symptoms (pain, function, quality of life, swelling and 128 
tenderness), and walking speed. These are described more fully in the following sections and in 129 
Supplement Table 1.  130 
 131 
Radiographic Assessments 132 
We used bilateral weight-bearing, fixed-flexion posteroanterior knee radiographs to 133 
assess two radiographic variables: femorotibial angle (FTA) and coronal tibial slope.  134 
Femorotibial angle was measured to assess static knee alignment. We used the publicly 135 
available data on the OAI website (file: KXR_FTA_Duryea00, version 0.2).10 In brief, a 136 
customized software tool defined the tibial axis based on the central point of the knee and the 137 
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center of the tibial diaphysis at approximately 10 cm distal to the tibial plateau. The femoral axis 138 
was perpendicular to a line tangent to the distal ends of the medial and lateral femoral condyles. 139 
The software tool calculated the angle between the tibial and femoral axis with negative values 140 
indicating knees with more varus alignment. FTA was adjusted to match hip-knee-ankle angles 141 
as described in Iranpour-Boroujeni et al.11 Intra-reader and inter-reader ICCs were >0.95.10 142 
Coronal tibial slope was assessed by one reader (JBD) using an EFilm Workstation 3.4 143 
(Merge Healthcare, Chicago, IL).12 The reader identified the longitudinal tibial axis and drew a 144 
line connecting the peak points of the medial and lateral aspects of the tibial plateau. He then 145 
moved the longitudinal axis to the lateral aspect of the tibial plateau and drew a line 146 
perpendicular to the longitudinal axis. A positive coronal tibial slope indicated that the peak 147 
lateral aspect of the tibial plateau was proximal to the peak medial aspect. The intra-reader 148 
reliability was good (ICC3,1=0.87, n=15 knees).13  149 
 150 
Demographic Characteristics 151 
We included publicly available age, sex, and body mass index, which study staff 152 




Study staff performed blood draws at the baseline visit. Participants fasted for at least 8 157 
hours prior to the blood draw. Blood samples were centrifuged and aliquoted into cryovials. 158 
Samples were stored in a -70°C freezer prior to shipping to Fisher Bioservices (Rockville, MD) 159 
for long-term storage. Protocols for the biospecimens collection and processing are available on 160 
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the OAI website.10 Fisher Bioservices shipped the serum samples to Temple University School 161 
of Medicine in September 2015. One investigator (MA) performed all assays in duplicate. We 162 
used commercially available enzyme-linked immunosorbent assay kits to assess high-sensitivity 163 
C-reactive protein (Novex by Life Technology, Carlsbad, CA) and glycated serum protein 164 
(MyBiosource, San Diego, CA). The Abcam Glucose Assay Kits were used to assess serum 165 
glucose (after deproteinization). Further details about the biospecimen analysis for this study 166 
were previously described.14  167 
 168 
Symptoms 169 
In addition to the measures in the previously published CART model (described above),5 170 
we included clinically accessible pain, function, clinical knee exam, and quality of life measures 171 
in our base model. All data are publicly available (File: allclinical00, version 0.2.2).10  172 
The Western Ontario and McMaster (WOMAC) Universities Osteoarthritis Pain Scale 173 
(3.1 Likert version) was used to assess self-reported knee-specific pain within the last 7 days 174 
separately for each knee (range 0-20, with higher scores indicating higher pain).15 The scale is 175 
based on 5 questions about pain, each scored from 0 (no pain) to 4 (extreme pain).  (The 176 
WOMAC Function Scale (3.1 Likert version) function scores range from 0-68, with higher 177 
scores indicating greater functional impairment. The scale is based on 17 questions, each scored 178 
from 0 (no impairment) to 4 (extreme impairment). 179 
Separately, participants were asked whether “during the past twelve months, have you 180 
had pain, aching or stiffness, in or around your right knee, on most days for at least one month? 181 
By most days, we mean more than half the days in one month.” Possible responses were yes or 182 
no. A similar question was asked about the left knee. 183 
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Participants also self-reported impact of KOA on quality of life via the Knee Injury and 184 
Osteoarthritis Outcome Score (KOOS) quality of life subscale.16 Possible scores range from 0-185 
100, with higher scores indicating better quality of life. 186 
Bilateral clinical knee exams were performed at baseline to determine the presence of 187 
crepitus, tenderness and/or swelling. Specifically, we included patella-femoral crepitus, lateral 188 
and medial joint line tenderness, patella tenderness, knee swelling evidenced by a positive bulge 189 
sign or patellar tap test, and patellar/quadriceps tenderness/tendonitis. 190 
 191 
Physical Function 192 
Habitual walking speed was assessed via 2 timed 20-meter talks. The time needed to 193 
complete the 20-meters was converted to walking speed (i.e. meters/second [m/s]) and averaged 194 
across the two trials. All data are publicly available (File: allclinical00, version 0.2.2).10 195 
 196 
MR-based Features Added to the CART 197 
Magnetic Resonance Imaging Acquisition 198 
Baseline MR images were acquired with one of four identical Siemens (Erlangen, 199 
Germany) Trio 3-Tesla MR systems at each clinical site using the OAI MR imaging protocol.10; 200 
17 Bone marrow lesion (BML) volume and effusion-synovitis volume quantitative measurements 201 
were performed using a sagittal intermediate-weighted, turbo spin echo, fat-suppressed MR 202 
sequence with the following parameters: field of view=160mm, slice thickness=3mm, 203 
skip=0mm, flip angle=180 degrees, echo time=30ms, recovery time=3200ms, 313x448 matrix, x 204 
resolution=0.357mm, y resolution=0.511mm, and total slice number=37. Articular cartilage was 205 
quantified using a 3-dimensional dual-echo steady-state sequence with the following parameters: 206 
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field of view=140mm, slice thickness=0.7mm, skip=0mm, flip angle=25 degrees, echo 207 
time=4.7ms, recovery time=16.3ms, 307x384 matrix, x resolution=0.365mm, y 208 
resolution=0.456mm, and total slice number=160. Musculoskeletal radiologists assessed semi-209 
quantitative or dichotomous MR-based features using all MR sequences for each visit. 210 
 211 
Bone Marrow Lesion Volume 212 
One reader (ACS), unaware of group assignment, measured tibiofemoral BML volume 213 
with a semi-automated segmentation software.18; 19 The only manual step required the reader to 214 
identify crude boundaries of the tibia and femur in each slice of the MR sequence. The boundary 215 
furthest from the articular surfaces was marked just prior to the epiphyseal line or at the edge of 216 
the bone and soft tissue. The program then automatically identified the precise bone boundaries 217 
and performed a thresholding and curve evolution process twice to segment areas of high signal 218 
intensity, which may represent a BML. We eliminated false-positive regions by operationally 219 
defining a BML based on 2 criteria: 1) the distance between a BML to the articular surface 220 
should be <10 mm, and 2) a BML needed to span more than one MR image. The study principal 221 
investigator reviewed all measurements. Our reader demonstrated excellent intra-reader 222 
reliability (ICC3,1=0.91). Total tibiofemoral BML volume was used in the analysis. 223 
 224 
Effusion-Synovitis Volume  225 
We used a semi-automated segmentation software to measure knee effusion-synovitis, 226 
which reflects effusion and synovitis volume.6 Two readers (JBD and FA) used the software to 227 
mark the first and last MR slice that included bone, the proximal border of the patella, and the 228 
apex of the fibular head. The software then automatically segmented effusion-synovitis between 229 
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these limits based on an existing threshold. The senior reader (JBD) then manually adjusted the 230 
threshold to change the effusion-synovitis boundaries and removed areas of high-signal intensity 231 
that were not effusion-synovitis (e.g., subchondral cysts, blood vessels). The senior reader 232 
demonstrated excellent intra-reader reliability (ICC3,1=0.96). Whole knee effusion-synovitis 233 
volume was used in the analysis. 234 
 235 
Cartilage Damage Index 236 
To measure tibiofemoral cartilage we used the validated cartilage damage index (CDI).20; 237 
21 One reader (JED) manually marked the bone-cartilage boundary on specific knee slices that 238 
are automatically selected based on the presence of predefined informative locations.20; 21 The 239 
reader then measured cartilage thickness at predefined 36 informative locations, which the 240 
software automatically located. The software then computed the CDI for the medial femur, 241 
lateral femur, medial tibia, and lateral tibia by summing the products of cartilage thickness, 242 
cartilage length (anterior-posterior), and voxel size from 9 informative locations in each region. 243 
The study principal investigator reviewed all measurements. Our reader demonstrated excellent 244 
intra-reader reliability (ICC3,1=0.86 to 0.99). CDI in the medial and lateral compartments of the 245 
tibial and femoral were used in the analysis. 246 
 247 
Semi-quantitative Features 248 
Two musculoskeletal radiologists (RW:255 cases, JM:120 cases) performed the semi-249 
quantitative MR readings. Readers had good agreement on the presence of each pathology 250 
among 25 cases: prevalence-adjusted and bias-adjusted kappa were 0.41 to 0.75 except for the 251 
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posterior horn of the medial meniscus where the prevalence-adjusted and bias-adjusted kappa 252 
was fair at 0.25 (50% agreement).  253 
The radiologists assessed the integrity of anterior/posterior cruciate ligaments, 254 
medial/lateral collateral ligaments, extensor mechanism, and gastrocnemius proximal tendons by 255 
noting if the structures appeared normal or degenerative. Degenerative tissue was defined as the 256 
presence of abnormal intrinsic high-signal intensity within the substance of the ligaments or 257 
tendon without discrete tear. Degenerative cruciate ligament pathology combined the presence of 258 
anterior or posterior cruciate ligament degenerative pathology. Degenerative collateral ligament 259 
pathology combined the presence of medial or lateral collateral ligament degenerative pathology. 260 
The radiologists scored infrapatellar fat pad signal intensity alteration using the MR 261 
Imaging Osteoarthritis Knee Score grading system (i.e., normal, mild, moderate, and severe).22 262 
Infrapatellar fat pad signal intensity was recoded as absence (i.e., normal) or presence (i.e., mild, 263 
moderate, and severe).  264 
The radiologists scored medial and lateral meniscus extrusion using the MR Imaging 265 
Osteoarthritis Knee Score grading system (i.e., Grade 0: <2 mm, Grade 1: 2 to 2.9 mm, Grade 2: 266 
3 to 5 mm, and Grade 3: >5mm).22 Meniscal extrusion was recoded as absence (i.e., Grade 0) or 267 
presence (i.e., > Grade 1). 268 
The radiologists used the International Society of Arthroscopy, Knee Surgery, and 269 
Orthopaedic Sports Medicine meniscal tear classification, which was modified for MR 270 
imaging23, to assess the body, posterior/anterior horn of each meniscus as: normal, degeneration, 271 
horizontal, flap horizontal, vertical longitudinal, radial, morphologic deformity, maceration, 272 
complex, or vertical flap tear. Meniscal pathology was recoded as absence (i.e., normal or 273 
degeneration without tear) and presence (i.e., horizontal, flap horizontal, vertical longitudinal, 274 
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radial, morphologic deformity, maceration, complex, or vertical flap tear). The medial/lateral 275 
menisci were considered pathologic if pathology was present in any of the three regions (body or 276 
anterior/posterior horn). Additionally, we determined the number of pathologic meniscal regions 277 
with meniscal pathology, which could range from 0-6 (i.e., medial/lateral and 278 
anterior/body/posterior horn).   279 
The radiologists were also asked to record the presence of any other miscellaneous 280 
pathology: attrition, acute ligamentous or tendinous injuries, subchondral insufficiency fractures, 281 
and any other incidental findings. Attrition was assessed from 0 (normal) to 3 (severe), based on 282 
the perceived degree of deviation from a normal contour for the medial and lateral femur and 283 
tibia. We defined the presence of attrition as a score of 1 or more. We defined acute ligamentous 284 
or tendinous injury as per routine clinical practice, using the presence/absence of focal fiber 285 
disruption and intrinsic ligamentous or subjacent soft tissue edema to detect the presence of 286 
injury. We defined subchondral insufficiency fracture as a linear low signal in the subchondral 287 
bone on a fat suppressed image and subjacent edema. Since each of these pathologies were rare, 288 
we combined them into a single outcome variable: presence or absence of miscellaneous 289 
pathology. 290 
 291 
Statistical Analysis 292 
We performed classification and regression tree (CART) analyses to determine 293 
classification rules and important variables for: 1) a model with MR variables only, 2) a base 294 
model with clinically accessible variables (i.e., serological, radiographic, demographic, 295 
symptoms, and physical function), and 3) a combined model with all clinically accessible 296 
variables and MR-based measures as candidate variables.  297 
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CART is a non-parametric method that has some advantages over other statistical 298 
techniques for classification by allowing for complex interactions and non-linear associations. 299 
This method identifies the most discriminating risk factor, with its associated cut point, to 300 
differentiate the two groups (e.g. accelerated KOA or no accelerated KOA). After the initial split 301 
based on the cut point, CART iteratively finds the next best risk factors with their corresponding 302 
associated cut point. CART analysis identifies the most important risk factors and is easily 303 
interpretable. The identification of important variables is obtained by creating multiple trees via 304 
cross-validation, and observing which variables appear in most of the trees.24  305 
Pruning and 10-fold cross-validation were performed to avoid overfitting and to identify 306 
the most important variables. Sensitivity and specificity were calculated for all models. All 307 
analyses were performed using the rpart function in R (version 3.4.4, The R Foundation for 308 
Statistical Computing). 309 
 310 
RESULTS 311 
Fifty-four cases (accelerated KOA) and 108 participants in the control group (54 adults 312 
with typical KOA and 54 adults with no KOA) met the inclusion criteria at baseline. This cohort 313 
has been described previously.5 In brief, the sample was predominantly female (63%), with mean 314 
age 59 years (SD=8), and body mass index 28 kg/m2 (SD=5). 315 
 316 
Model 1: CART with MR Features Only 317 
Figure 1 displays the CART model with only MR features to see which features are 318 
associated with development of accelerated KOA. Effusion-synovitis volume, BML volume, and 319 
presence of cruciate ligament degeneration were the three most important variables (in order of 320 
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importance). Individuals with a higher effusion-synovitis volume (≥14 cc) were likely to develop 321 
accelerated KOA over the subsequent 4 years. Participants with a lower effusion-synovitis 322 
volume but larger BML volume (>0.24 cc) were less likely to develop accelerated KOA. In 323 
contrast, adults with lower effusion-synovitis and BML volumes and cruciate ligament 324 
degeneration were more likely to develop accelerated KOA. This model explained 31% of the 325 
variability, with specificity of 0.88 and sensitivity of 0.57. 326 
 327 
 328 
Model 2: Base Model - Previously Published Model + Symptoms and Function 329 
Figure 2 presents the base model based on clinically accessible variables.7 Baseline 330 
serum glucose, age, and static alignment were the three most important variables (in order of 331 
importance). The first 3 cuts were based on age, serum glucose, and BMI. Most individuals <64 332 
years did not develop accelerated KOA over the subsequent 4 years, except for those with body 333 
mass index ≥34 kg/m2 and those with body mass index <34 kg/m2 but more impaired WOMAC 334 
function (≥8.8) and coronal tibia slope≥4 degrees (a more proximal lateral plateau than medial). 335 
Conversely, all of the adults 64 or older with glucose<82 developed accelerated KOA. This 336 
model explained 41% of the variability and had specificity of 0.82 and sensitivity of 0.70.   337 
 338 
Model 3: Base Model + MR Features  339 
Figure 3 displays the CART with all candidate variables placed in the model. Effusion-340 
synovitis volume, serum glucose, and the presence of cruciate ligament degeneration were the 341 
most important variables (in order of importance). Overweight or obese individuals with higher 342 
effusion-synovitis volume (≥14 cc) were more likely to develop accelerated KOA over the 343 
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subsequent 4 years. Participants with lower effusion-synovitis volume (<14 cc) and glucose <67 344 
were also likely to develop accelerated KOA. The presence of cruciate ligament degeneration 345 
and coronal tibial slope played a role in classification of individuals with lower effusion-346 
synovitis volume and glucose≥67. This model explained 39% of the variance and had specificity 347 
of 0.90 and sensitivity of 0.62.  348 
 349 
DISCUSSION 350 
We expanded on prior work to classify adults at risk for accelerated KOA by adding 351 
baseline clinical, symptomatic, and MR measures to a CART. Our primary goal was to assess 352 
whether adding MR measures in isolation or combined to our base model could improve the 353 
classification of individuals at risk for developing accelerated KOA within the subsequent four 354 
years. Variables that consistently appeared in the models, and that may enable classification of 355 
individuals at risk of developing accelerated KOA, were effusion-synovitis volume, presence of 356 
cruciate ligament degeneration, and serum glucose. The addition of an array of MR variables to 357 
the base model failed to improve model fit (percent of variance explained ~40% for both 358 
models). 359 
Based our prior analyses2; 4, we hypothesized that the addition of baseline pain, function 360 
and quality of life measures would improve the classification of adults who will develop 361 
accelerated KOA in the subsequent 4 years. While the model with these measures showed some 362 
improvement in terms of the percent of variability explained (41% vs 31% in previously 363 
published model5), WOMAC function was the only symptom, function, or quality of life variable 364 
that was selected by the model. We also hypothesized that the addition of MR measures would 365 
improve classification of adults who will develop AKOA, based on prior analyses.2; 6-9 However, 366 
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the base model + MR features explained slightly less variability than the base model alone (39% 367 
vs 41%).  The full model also had lower sensitivity (0.62 vs 0.70) but higher specificity (0.90 vs 368 
0.82) compared to the base model.  369 
This lack of substantial improvement in classification after adding variables such as pain 370 
that have been shown to be associated with development of accelerated knee osteoarthritis may 371 
be explained by the fact that CART’s strength is in classification rather than prediction or 372 
strength of association. There may be other variables that are more relevant in classification than 373 
pain. Additionally, the interactions may identify subsets of people that are more at risk based on 374 
their combined characteristics, rather than pain alone. 375 
In spite of the improvements in the percent of variability explained by the models with 376 
symptoms and MR, 60% of the variance remains unexplained. The cost of obtaining self-377 
reported function, pain, and quality of life is minimal and clinicians and researchers may 378 
consider including them when assessing risk for development of accelerated KOA. MR 379 
measurement costs, on the other hand, can be quite substantial. It is not clear that there is a 380 
sufficient increase in precision of the classification to warrant the additional cost. Identification 381 
of novel risk factors may improve classification. 382 
Both effusion-synovitis volume and cruciate ligament degeneration are consistently 383 
identified as important MR-based features for the classification of accelerated KOA. This 384 
complements prior work where we observed effusion-synovitis volume was greater among adults 385 
who developed accelerated KOA up to 2 years prior to radiographic onset compared with adults 386 
with typical or no KOA.6 Furthermore, these results agree with preliminary results that cruciate 387 
ligament degeneration is more common among adults who developed accelerated KOA up to 2 388 
years prior to radiographic onset compared with adults with typical or no KOA.25 These MR-389 
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based findings may be some of the earliest manifestations of accelerated KOA, which could help 390 
shed light on why some adults develop accelerated KOA.  391 
Despite previous findings that fasting serum glucose was not significantly associated with 392 
either prevalent or incident KOA26-29, we identified fasting serum glucose as a potentially 393 
important variable for classifying people who will develop accelerated KOA. While this finding 394 
is surprising, it may be explained by CART’s ability to detect possible interactions with small 395 
sample sizes, whereas standard statistical analyses would not be powered to detect interactions. 396 
For example, the CART results suggest that glucose may be an important factor among older 397 
adults, but not among younger adults. It may be useful to explore the association between fasting 398 
glucose levels and development of accelerated KOA among adults 64 years and older. 399 
CART is useful as an exploratory method to help identify possible risk factors and 400 
interactions that are not possible with regression in studies with limited sample size. The CART 401 
results suggest that there may be interactions between age, BMI, and glucose in the base model.  402 
There may also be interactions between effusion-synovitis volume and BMI, as well as effusion-403 
synovitis volume and glucose. Future studies sufficiently powered to detect interactions will be 404 
important in improving classification of people at risk of developing accelerated KOA. 405 
While this study has identified potential new risk factors and possible interactions, we 406 
acknowledge that there are limitations.  We have not yet replicated this model in an external 407 
dataset. Although external validation is a critical future project, we are still in the development 408 
stage of model development. Our best model still has a significant amount of unexplained 409 
variation and we feel this needs to be addressed by identification and inclusion of novel risk 410 
factors before proceeding to a standard development and validation model. Despite this 411 
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limitation, we believe this study is an important step towards classifying adults who will develop 412 
accelerated KOA. 413 
In conclusion, acquisition of MR images for common structural features to identify individuals at 414 
risk of developing accelerated KOA in the subsequent four years may not be justified due to the 415 
high cost of obtaining them and the minimal effect on classification compared to the base model. 416 
We also found that serum glucose, effusion-synovitis volume, and cruciate ligament 417 
degeneration are important variables in the classification of individuals at risk for accelerated 418 
KOA in the next four years. However, all models continue to have ~60% of the variability 419 
unexplained, indicating a need for future research to identify novel risk factors that will improve 420 
the classification.  421 
 422 
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FIGURE LEGENDS 534 
Figure 1: Classification and Regression Tree with Features on Magnetic Resonance Images 535 
Only 536 
Abbreviations: Effusion=effusion-synovitis, BML=bone marrow lesion, AKOA=accelerated 537 
knee osteoarthritis 538 
 539 
Figure 2: Classification and Regression Tree Base Model: Previously Published Model with 540 
Symptoms and Function Added 541 
Abbreviations: BMI=body mass index, AKOA=accelerated knee osteoarthritis 542 
 543 
Figure 3: Classification and Regression Tree Base Model and Features on Magnetic 544 
Resonance Images  545 
Abbreviations: Effusion=effusion-synovitis, BMI=body mass index, AKOA=accelerated knee 546 
osteoarthritis 547 
 548 
 549 
